Prelude Therapeutics Incorporated PRLD
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 24.54% | -18.79% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.54% | -18.79% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 24.54% | -18.79% | |||
| SG&A Expenses | -2.50% | 5.31% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.80% | -13.51% | |||
| Operating Income | -9.01% | 11.66% | |||
| Income Before Tax | -34.05% | 36.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -34.05% | 36.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -34.05% | 36.90% | |||
| EBIT | -9.01% | 11.66% | |||
| EBITDA | -9.54% | 11.80% | |||
| EPS Basic | -12.48% | 39.08% | |||
| Normalized Basic EPS | -12.33% | 33.75% | |||
| EPS Diluted | -12.48% | 39.08% | |||
| Normalized Diluted EPS | -12.33% | 33.75% | |||
| Average Basic Shares Outstanding | 19.23% | 3.52% | |||
| Average Diluted Shares Outstanding | 19.23% | 3.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||